epocrates logo
epocrates logo
epocrates logo
  • 0

Journal Article Synopsis

Nature

Blood test may reveal breast cancer’s hidden risk

November 13, 2026

card-image

Clinical takeaway: An experimental blood test detected luminal breast cancer and identified epigenetic signals associated with recurrence within 5 years. The retrospective findings warrant prospective validation before the test can guide screening, surveillance, or treatment decisions.

Hormone receptor–positive breast cancers generally respond to endocrine therapy, yet some recur despite apparently favorable features. Differences among cells within the same tumor may help explain this risk, and could provide clues that conventional tumor classification misses.

Researchers identified a small population of basal-like cells within each luminal tumor examined, with reduced hormone receptor signaling and molecular features associated with aggressive behavior. These cells carried distinctive chemical modifications on histones, the proteins around which DNA is packaged.

The experimental EPINUC assay measured related epigenetic signals in blood, detecting 85% of luminal cancers and correctly classifying 92% of healthy controls in a held-out, multicenter test set of 47 samples. Separate analyses also showed strong discrimination between healthy controls and patients with small, T1 tumors, with performance appearing unaffected by breast density.

Blood samples collected before surgery also contained signals associated with subsequent recurrence, including modifications enriched in basal-like tumor cells. Recurrence models achieved areas under the receiver operating characteristic curve of 0.81 in the initial cohort and 0.92 in a second, smaller cohort; these measures describe discrimination, rather than the percentage of patients correctly classified.

The investigators combined single-cell epigenetic profiling of 12 untreated breast tumors, predominantly luminal cancers, with retrospective blood analyses and machine-learning models. The principal clinical outcomes assessed were discrimination between cancer and healthy samples and recurrence within 5 years; the initial prognostic cohort included 77 patients, of whom 33 developed recurrence.

Larger prospective studies must establish whether these signals improve clinical decisions and outcomes. For now, the findings support further investigation of a blood test that could capture tumor biology beyond a single tissue sample.

“Whether epigenetic therapies can limit plasticity and state transitions remains to be tested,” the authors wrote, highlighting a potential therapeutic direction.

Source: Furth N, et al. (2026 Nov 11) Nature. Epigenetic heterogeneity in breast tumours informs diagnosis and prognosis

learn more about epocrates plus

Clinical FAQs

Check out the answers to frequently asked questions about our clinical content.

Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & FeedbackCookie Preferences
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information